DiaMedica doses first patient in Phase 2/3 stroke trial; Q3 cash $48.1M after $30M raise

DiaMedica Therapeutics Inc.

First patient dosed in pivotal ReMEDy2 trial of DM199 for acute ischemic stroke; ~350 patients planned.
FDA granted Fast Track Designation for DM199 in AIS; protocol amendment adds stroke recurrence as primary endpoint.
Completed $30M private placement in Sept 2021; cash, equivalents and marketable securities $48.1M at Sept 30.
Q3 2021 R&D expenses $2.3M (vs $2.2M Q3 2020); net cash used in ops $9.4M for 9 months.
Additional REDUX Phase 2 data in IgAN showed >30% reduction in albuminuria at ASN Kidney Week.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.